Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Levodopa: 50 years of a revolutionary drug for Parkinson disease
Stanley Fahn, Werner Poewe
Movement Disorders (2014) Vol. 30, Iss. 1, pp. 1-3
Closed Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Pathological α‐synuclein in gastrointestinal tissues from prodromal Parkinson disease patients
Morten Gersel Stokholm, Erik Hvid Danielsen, Stephen Hamilton‐Dutoit, et al.
Annals of Neurology (2016) Vol. 79, Iss. 6, pp. 940-949
Closed Access | Times Cited: 353
European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part II: psychological interventions
Per Andrén, Ewgeni Jakubovski, Tara Murphy, et al.
European Child & Adolescent Psychiatry (2021) Vol. 31, Iss. 3, pp. 403-423
Open Access | Times Cited: 111
Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease
Michael M. Lipp, Richard Batycky, Jerome A. Moore, et al.
Science Translational Medicine (2016) Vol. 8, Iss. 360
Closed Access | Times Cited: 67
Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential
Dahua Fan, Liping Liu, Zhengzhi Wu, et al.
Current Neuropharmacology (2018) Vol. 17, Iss. 6, pp. 563-579
Open Access | Times Cited: 62
Consensus on the treatment of dysphagia in Parkinson's disease
Antonio Schindler, Nicole Pizzorni, Emanuele Cereda, et al.
Journal of the Neurological Sciences (2021) Vol. 430, pp. 120008-120008
Open Access | Times Cited: 49
Probiotics Treatment Improves Hippocampal Dependent Cognition in a Rodent Model of Parkinson’s Disease
Caroline Xie, Asheeta A. Prasad
Microorganisms (2020) Vol. 8, Iss. 11, pp. 1661-1661
Open Access | Times Cited: 40
Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases
Claudia Riccardi, Filomena Napolitano, Daniela Montesarchio, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1897-1897
Open Access | Times Cited: 35
Advancing age and sex modulate antidyskinetic efficacy of striatal CaV1.3 gene therapy in a rat model of Parkinson’s disease
Margaret E. Caulfield, Molly Vander Werp, Jennifer A. Stancati, et al.
Neurobiology of Aging (2025) Vol. 149, pp. 54-66
Open Access
Model-based dietary optimization for late-stage, levodopa-treated, Parkinson’s disease patients
Marouen Ben Guebila, Ines Thiele
npj Systems Biology and Applications (2016) Vol. 2, Iss. 1
Open Access | Times Cited: 43
Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson’s disease
Si-Chun Gu, Zhiguo Xie, Min-Jue Gu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia
Renata P. Lerner, Veronica Francardo, Koji Fujita, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 36
Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's
Atbin Djamshidian, Werner Poewe
Parkinsonism & Related Disorders (2016) Vol. 33, pp. S9-S12
Closed Access | Times Cited: 34
Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia
Vincent A. Jourdain, Chris C. Tang, Florian Holtbernd, et al.
JCI Insight (2016) Vol. 1, Iss. 15
Open Access | Times Cited: 32
Computer Aided Drug Design Studies in the Discovery of Secondary Metabolites Targeted Against Age-Related Neurodegenerative Diseases
Luciana Scotti, Luciana Scotti
Current Topics in Medicinal Chemistry (2015) Vol. 15, Iss. 21, pp. 2239-2252
Closed Access | Times Cited: 31
Voice quality severity and responsiveness to levodopa in Parkinson’s disease
Daryn Cushnie-Sparrow, Scott Adams, Anita Abeyesekera, et al.
Journal of Communication Disorders (2018) Vol. 76, pp. 1-10
Closed Access | Times Cited: 28
One-step continuous synthesis of functionalized magnetite nanoflowers
Guillaume Thomas, Frédéric Demoisson, Rémi Chassagnon, et al.
Nanotechnology (2016) Vol. 27, Iss. 13, pp. 135604-135604
Closed Access | Times Cited: 26
A survey of subjective constipation in Parkinson’s disease patients in shanghai and literature review
Jing Gan, Ying Wan, Junjie Shi, et al.
BMC Neurology (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 25
Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease
Marcus Pieterman, Scott Adams, Mandar Jog
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 19
Exposição a agrotóxicos na agricultura e doença de Parkinson em usuários de um serviço público de saúde do Paraná, Brasil
Paula Renata Olegini Vasconcellos, Maria Lúcia Frizon Rizzotto, Phallcha Luízar Obregón, et al.
Cadernos Saúde Coletiva (2020) Vol. 28, Iss. 4, pp. 567-578
Open Access | Times Cited: 16
Dopaminergic modulation of positive expectations for goal-directed action: evidence from Parkinson’s disease
Noham Wolpe, Cristina Nombela, James B. Rowe
Frontiers in Psychology (2015) Vol. 6
Open Access | Times Cited: 15
Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson’s Disease: A Retrospective Study
Mayela Rodríguez‐Violante, Adib Jorge de Saráchaga, Amin Cervantes‐Arriaga, et al.
Journal of Parkinson s Disease (2016) Vol. 6, Iss. 1, pp. 183-190
Closed Access | Times Cited: 14
Effect of opicapone multiple‐dose regimens on levodopa pharmacokinetics
José‐Francisco Rocha, Éric Sicard, Nicolas Fauchoux, et al.
British Journal of Clinical Pharmacology (2016) Vol. 83, Iss. 3, pp. 540-553
Open Access | Times Cited: 14
The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinson’s Disease
Margaret E. Caulfield, Fredric P. Manfredsson, Kathy Steece‐Collier
Handbook of experimental pharmacology (2023), pp. 107-137
Closed Access | Times Cited: 4
Treatment of Parkinson's Disease
Deepmala Nandanwar, Daniel Truong
Elsevier eBooks (2024)
Closed Access | Times Cited: 1
Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA
Andrew J. Lees, Joaquim J. Ferreira, Olivier Rascol, et al.
Expert Review of Neurotherapeutics (2017) Vol. 17, Iss. 7, pp. 649-659
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top